Valeant Is Tanking
Here’s why my new price target on VRX is $100/share

Last week I called out drug company Valeant Pharmaceuticals International Inc. (NYSE:VRX) as a bad investment and a stock that’s going down.

I showed you how it operates as a highly leveraged “serial acquirer” that buys other companies only to fire their workers and hike the prices of their drugs.

I also told you the company’s strategy was about to backfire.

But that happened faster than even I expected…

To continue reading click here.

This Stock Is Everything That’s Wrong with the Markets

[BREAKING] As we published this Thursday morning, news broke that Valeant is now under federal investigation in Massachusetts and New York for its drug-pricing practices. VRX shares were down -11.5% at open. Stay tuned here.

Every once in a while, a single company combines virtually all of the market’s most toxic forces. Today I feel it’s my job to expose such a company for the bad investment it is. Here’s why.

  1. It’s got a risky and predatory business model.
  1. It’s leveraged up to the hilt, with $30 billion of debt on just $9 billion in revenue in the trailing 12 months.
  1. It’s on the radar of politicians, which is trouble for shareholders.

And here’s the real problem…

  1. It’s widely owned by investors like you. Even if you don’t realize it, you may own this stock in any of the seven ETFs that hold it as a component.

Already the stock dropped -25% in September. In a Super Crash, it’s going to be much worse. This stock is a yo-yo. It gained +6.48% yesterday, but the day before it lost -4.21%.

And it’s really in trouble now.

To continue reading click here.

View this page online: